SEARCH

SEARCH BY CITATION

References

  • 1
    Imbert-Bismut F, Ratziu V, Laurence Pieroni L, Charlotte F, Benhamou Y, Poynard T for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:10691075.
  • 2
    Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9:128133.
  • 3
    Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97:24192425.
    Direct Link:
  • 4
    Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003; 17:15.
  • 5
    Myers RP, de Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and the age-platelet index. Dig Dis Sci 2003; 48:146153.
  • 6
    Thabut D, Simon M, Myers RP, Messous D, Thibaut V, Imbert-Bismut F, Poynard T. Noninvasive prediction of fibrosis in patients with chronic hepatitis C [letter]. Hepatology 2003; 37:12201221.
  • 7
    Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49:450454.
  • 8
    Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107:27S30S.
  • 9
    Poynard T, Ratziu V, Benhamou Y, Di Martino VD, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000; 20:4755.
  • 10
    Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 2002: 36;S152S160.
  • 11
    Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36:S161S172.
  • 12
    Consensus Statement. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30:956961.
  • 13
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R, Goodman ZD, et al. Peg-Interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358:958965.
  • 14
    Knodell KG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kieman TW, et al. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431435.
  • 15
    The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20:1520.
  • 16
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289293.
  • 17
    Hintze JL. NCSS 97 User Guide. Number Cruncher Statistical Systems. Kaysville, Utah, 1997.
  • 18
    Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36:973977.
  • 19
    Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42:558563.
  • 20
    Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113:16091616.
  • 21
    Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986992.
  • 22
    Poynard T, Vlad Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, et al. The effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38:7585.
  • 23
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825832.
  • 24
    Guillen MI, Gomez-Lechon MJ, Nakamura T, Castell JV. The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes. Hepatology 1996, 23:13451352.
  • 25
    Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 1999, 276:G1059G1068.
  • 26
    Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of α2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci 1998; 95:179186.
  • 27
    Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000, 32:14031408.
  • 28
    Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of α2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Colch) 1998, 95:179186.
  • 29
    Poynard T, Bedossa P, Mathurin P, Ratziu V, Paradis V. Apolipoprotein A1 and hepatic fibrosis. J Hepatol 1995; 22:107110.
  • 30
    Paradis V, Mathurin P, Ratziu V, Poynard T, Bedossa P. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Hepatology 1996, 23:12321238.
  • 31
    Mathurin P, Vidaud D, Vidaud M, Bedossa P, Paradis V, Ratziu V, Chaput JC. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology 1996; 23:4451.
  • 32
    Paradis V, Laurent A, Mathurin P, Poynard T, Vidaud D, Vidaud M, Bedossa P. Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. Cell Mol Biol 1996; 42:525534.
  • 33
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology 2000; 32:477481.
  • 34
    Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. Liver 1982; 2:369375.
  • 35
    Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14:543548.
  • 36
    Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 8480:523525.
  • 37
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:26142618.
    Direct Link:
  • 38
    Clark GH, Fraser CG. Biological variation of acute phase proteins. Ann Clin Biochem 1993; 30:373376.
  • 39
    Maes M, Cooreman W, Delanghe J, Scharpe S, Wauters A, Neels H, D'Hondt P, et al. Components of biological variation in plasma haptoglobin: relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor. Clin Chim Acta 1995; 239:2335.
  • 40
    Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002; 1:37.
  • 41
    Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, et al. Modeling the impact of alfa interferon treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116:378386.
  • 42
    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517524.
  • 43
    Shiffman ML, Hofmann CM, Contos J, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:11641172.
  • 44
    Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:11311137.
  • 45
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MS, et al. Impact of interferon, pegylated interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:13031313.
  • 46
    Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:11171123.